{"entity":{"id":"antigen-expression-and-response","kind":"term","name":"Antigen expression and treatment response","aka":["target expression versus ADC response","antigen density and ADC response"],"tldr":"Finding a surface protein can help explain how an antibody drug reaches a tumor. The amount of protein measured in a biopsy does not describe every step needed for the treatment to work.","summary":"Antigen measurement, drug uptake, intracellular processing and payload sensitivity describe different parts of antibody-drug conjugate activity. DAISY, a single-arm phase 2 study, examined trastuzumab deruxtecan across HER2 expression cohorts and found activity in more than one expression category. That study does not establish a universal expression cutoff or a comparative treatment effect in every cohort. A biomarker rule needs evidence for the particular drug, assay, disease and setting.","asOf":"2026-11-08","links":[{"label":"DAISY: variable HER2 expression and treatment activity (2023)","url":"https://doi.org/10.1038/s41591-023-02478-2"},{"label":"Cellular processing of a maytansinoid conjugate (2016)","url":"https://doi.org/10.1208/s12248-016-9892-3"}],"tags":[],"related":["ihc","biomarker","antibody-internalization-trafficking","prognostic-versus-predictive-biomarkers"],"cancers":[],"sections":[],"technologies":["adc"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"category":"ADC chemistry"},"route":"/terms/antigen-expression-and-response/","neighbours":{"term":[{"id":"antibody-internalization-trafficking","kind":"term","name":"Antibody internalization and intracellular trafficking","route":"/terms/antibody-internalization-trafficking/"},{"id":"binding-site-barrier","kind":"term","name":"Binding-site barrier in tumor delivery","route":"/terms/binding-site-barrier/"},{"id":"biomarker","kind":"term","name":"Biomarker","route":"/terms/biomarker/"},{"id":"measurement-to-benefit-evidence","kind":"term","name":"Evidence from measurement to patient benefit","route":"/terms/measurement-to-benefit-evidence/"},{"id":"ihc","kind":"term","name":"Immunohistochemistry (IHC)","route":"/terms/ihc/"},{"id":"prognostic-versus-predictive-biomarkers","kind":"term","name":"Prognostic and predictive biomarkers","route":"/terms/prognostic-versus-predictive-biomarkers/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"}]}}